Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 154Stomach Neoplasms 23Neoplasms 18Neoplasm Metastasis 17Esophageal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Adenocarcinoma 11Breast Neoplasms 9Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Carcinoma, Pancreatic Ductal 7Biliary Tract Neoplasms 7Lung Neoplasms 6Gallbladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Diseases 5Digestive System Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Endocrine Gland Neoplasms 4Digestive System Diseases 4Advanced Pancreatic Cancer 4Rectal Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3

Interventions

Radiofrequency Ablation 1Gemcitabine 1Albumin-Bound Paclitaxel 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholestasis × Albumin-Bound Paclitaxel × Gastrointestinal × Clear all
NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Celgene

Phase 1 Terminated
1 enrolled
Gastrointestinal

Cholestasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡